keyword
MENU ▼
Read by QxMD icon Read
search

Oligometastases

keyword
https://www.readbyqxmd.com/read/29774659/magnetic-resonance-imaging-evaluation-of-treatment-efficacy-and-prognosis-for-brain-metastases-in-lung-cancer-patients-after-radiotherapy-a-preliminary-study
#1
Yuhui Liu, Xibin Liu, Liang Xu, Liheng Liu, Yuhong Sun, Minghuan Li, Haiyan Zeng, Shuanghu Yuan, Jinming Yu
BACKGROUND: This study used magnetic resonance imaging (MRI) to monitor changes to brain metastases and investigate the imaging signs used to evaluate treatment efficacy and determine prognosis following radiotherapy for brain metastases from lung cancer. METHODS: A total of 60 non-small cell lung cancer patients with brain oligometastases were selected. MRI scans were conducted before and 3, 6, 9, 12, 18, 24, and 30 months after radiotherapy. The tumor and peritumoral edema diameters, Cho/Cr values, elevation of the Lip peak value, and whether the island (yu-yuan) sign or high-signal ring were present on T2 fluid-attenuated inversion recovery (FLAIR) imaging were recorded for each metastasis...
May 17, 2018: Thoracic Cancer
https://www.readbyqxmd.com/read/29774390/-oligometastases-in-gastric-and-esophageal-cancer-current-clinical-trials-and-surgical-concepts
#2
REVIEW
S Beckert, A Königsrainer
There is an increasing role of surgery even in metastatic tumor stages. In colorectal cancer patients with limited metastases, complete cytoreduction is able to offer long-term survival in synchronic as well as metachronic situations. In tumors of the upper gastrointestinal tract (UGIT), however, the impact of surgery in metastatic disease remains to be clarified. Even though several retrospective studies suggest prolonged survival, surgery is not recommended by the current German S3 guidelines for tumors of the UGIT...
May 17, 2018: Der Chirurg; Zeitschrift Für Alle Gebiete der Operativen Medizen
https://www.readbyqxmd.com/read/29767820/-role-of-visceral-surgery-in-oligometastases-of-non-gastrointestinal-tumors
#3
REVIEW
R Wahba, D Stippel, C Bruns
BACKGROUND: Patients with oligometastatic disease can benefit from local treatment of the metastases. Under these premises the resection of liver metastases and visceral metastases of non-gastrointestinal tumors is performed increasingly more frequently in selected patients. The aim of this study was to evaluate the role of visceral oncological surgery in hepatic oligometastatic disease of non-gastrointestinal tumors according to the currently available literature. MATERIAL AND METHODS: A systematic search of MEDLINE and PubMed was carried out focusing on the topics of oligometastases, liver resection and metastectomy for breast cancer, renal cell carcinoma, malignant melanoma, ovarian cancer and non-small cell lung cancer...
May 16, 2018: Der Chirurg; Zeitschrift Für Alle Gebiete der Operativen Medizen
https://www.readbyqxmd.com/read/29759332/sunset-stereotactic-radiation-for-ultracentral-non-small-cell-lung-cancer-a-safety-and-efficacy-trial
#4
Meredith Giuliani, Ashwathy S Mathew, Houda Bahig, Scott V Bratman, Edith Filion, Daniel Glick, Alexander V Louie, Srinivas Raman, Anand Swaminath, Andrew Warner, Vivian Yau, David Palma
BACKGROUND: Lung stereotactic body radiotherapy (SBRT) is considered a standard curative treatment for medically inoperable early stage non-small-cell lung cancer (NSCLC). Patients with ultracentral tumors (signifying tumors whose planning target volume touches or overlaps the central bronchial tree, esophagus, or pulmonary artery) may be at higher risk of serious toxicities such as bronchial stricture and collapse, esophageal strictures, tracheal-esophageal fistula, and hemorrhage. The primary objective of the study is to determine the maximum tolerated dose of radiotherapy for ultracentral NSCLC...
April 18, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29755104/-multidisciplinary-approach-to-recurrence-after-resection-of-primary-lung-cancer
#5
Mitsuhiro Kamiyoshihara, Hitoshi Igai, Takashi Ibe, Fumi Ohsawa, Ryohei Yoshikawa, Kimihiro Shimizu, Akira Mogi, Ken Shirabe, Hiroyuki Kuwano
BACKGROUND: The standard approach for treating recurrence after complete resection of primary non-small cell lung cancer has been controversial. We present here a multidisciplinary strategy for postoperative recurrence in patients with primary lung cancer. PATIENTS AND METHODS: Over the last 7 years, we examined the disease-free survival and overall survival of 70 patients who underwent multidisciplinary treatment for recurrence after surgical resection of primary lung cancer...
April 2018: Kyobu Geka. the Japanese Journal of Thoracic Surgery
https://www.readbyqxmd.com/read/29750538/stereotactic-body-radiation-therapy-for-liver-oligometastases-predictive-factors-of-local-response-by-18f-fdg-pet-ct
#6
Rosario Mazzola, Sergio Fersino, Pierpaolo Alongi, Gioacchino Di Paola, Fabiana Gregucci, Dario Aiello, Umberto Tebano, Stefano Pasetto, Ruggero Ruggieri, Matteo Salgarello, Filippo Alongi
OBJECTIVE: to investigate metabolic parameters as predictive of local response after Stereotactic Body Radiation Therapy (SBRT) for liver-oligometastases Methods: Inclusion criteria of the present retrospective study were: a) liver oligometastases with controlled primary tumor; b) absence of progressive disease ≥6 months; c) metastases ≤ 3; d) evaluation of SBRT-response by means of 18-FDG-PET/CT for at least two subsequent evaluations; e) Karnofsky performance status >80; f) life-expectancy >6 months...
May 11, 2018: British Journal of Radiology
https://www.readbyqxmd.com/read/29746284/the-concept-of-oligometastases-in-colorectal-cancer-from-the-clinical-evidences-to-new-therapeutic-strategies
#7
Edouard Massaut, Ali Bohlok, Valerio Lucidi, Alain Hendlisz, Jean Klastersky, Vincent Donckier
PURPOSE OF REVIEW: The concept of oligometastases, defining cancers with limited metastatic capacity and attaining a limited number of secondary sites, is now widely accepted, particularly in colorectal cancer. Currently, however, accurate predictive markers for oligometastatic tumors are still lacking. For this reason, it remains challenging to translate this concept into clinical recommendations. In the present work, we review recent publications on oligometastases in colorectal cancer, showing the evidences for such presentation and underlying the need for the identification of biomarkers, necessary to further develop new therapeutic strategies...
May 4, 2018: Current Opinion in Oncology
https://www.readbyqxmd.com/read/29737958/increased-efficacy-of-stereotactic-ablative-radiation-therapy-after-bevacizumab-in-lung-oligometastases-from-colon-cancer
#8
Rosario Mazzola, Umberto Tebano, Dario Aiello, Gioacchino Di Paola, Niccolò Giaj-Levra, Francesco Ricchetti, Sergio Fersino, Alba Fiorentino, Ruggero Ruggieri, Filippo Alongi
Aim Metastases from colorectal cancer are poorly responsive to stereotactic ablative radiation therapy (SABR) due to intratumoral hypoxia. Intratumoral oxygenation is improved by administration of angiogenesis inhibitors. Thus, there could be a clinical synergistic effect of SABR with bevacizumab on metastases from colorectal cancer. The aim of this study was to evaluate the feasibility and efficacy of SABR after bevacizumab in lung oligometastases from colon cancer. Methods The data of patients with lung metastases from colon cancer who underwent SABR were retrospectively evaluated according to the following inclusion criteria: number of metastases ≤3; lung oligometastases from colon cancer in patients who underwent SABR; patients receiving previous chemotherapy alone or in combination with bevacizumab; Karnofsky performance status >80; life expectancy >6 months; at least 6 months' follow-up after SABR; presence of KRAS mutation...
December 1, 2017: Tumori
https://www.readbyqxmd.com/read/29735409/comparison-of-survival-and-prognostic-factors-in-patients-treated-with-stereotactic-body-radiotherapy-for-oligometastases-or-oligoprogression
#9
Catherine A Pembroke, Bernard Fortin, Neil Kopek
BACKGROUND AND PURPOSE: Clinical challenges arise in the oligoprogressive (OP) state with little evidence to support the use of ablative strategies. Our aim is to report on outcomes and prognostic variables following stereotactic body radiotherapy (SBRT) for OP and oligometastases (OM). MATERIAL AND METHODS: Overall (OS) and progression-free survivals (PFS) were calculated for 163 patients for 209 lesions (106 OM and 57 OP) treated with SBRT over 9 years. OS and PFS comparisons were calculated using the Kaplan-Meier actuarial survival and log rank methods...
May 4, 2018: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/29722825/feasibility-of-split-course-stereotactic-ablative-radiotherapy-for-oligometastases
#10
Eun Kyung Paik, Mi-Sook Kim, Young-Seok Seo, Won Jang, Jin-Kyu Kang, Chul-Koo Cho, Hyung Jun Yoo
Background: There is growing interest in the use of stereotactic ablative radiotherapy (SABR) for oligometastases. However, extreme caution should be exercised in treating tumors closely located to organs at risk (OARs) with SABR. To reduce complications, we have applied split-course SABR to oligometastases closely located to OARs or to those being retreated with radiotherapy. Methods: We retrospectively reviewed the records of patients with oligometastases who were treated with planned split-course SABR between January 2012 and December 2016...
May 2, 2018: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29722493/-oligometastatic-breast-cancer-therapeutic-implications-of-a-new-paradigm
#11
B Méry, G Moriceau, A Vallard, J P Jacquin, N Magné
INTRODUCTION: Oligometastatic breast cancer incidence is recently increasing thanks to screening and imaging improvements. Unlike patients with metastatic disease, a small number of oligometastatic patients may expect a definitive remission, in case of aggressive management performed with intent to cure. We report the atypical evolution of an oligometastatic breast cancer patient, who lately relapsed with a different Her2 status. RESULTS: A 46 year old women was treated for an infiltrating duct breast carcinoma, initially diagnosed with oligometastases and an Her2- negative status...
2018: Revue Médicale de Bruxelles
https://www.readbyqxmd.com/read/29714665/stereotactic-body-radiotherapy-for-lung-oligometastases-literature-review-according-to-pico-criteria
#12
Filippo Alongi, Rosario Mazzola, Vanessa Figlia, Matthias Guckenberger
Exhaustive criteria and definitive data to identify the ideal lung oligometastatic patient as a candidate for stereotactic body radiotherapy (SBRT) are lacking. Three distinct cohorts of oligometastatic patients could be distinguished: (1) patients with upfront diagnosis of oligometastases (synchronous or metachronous); (2) patients with oligorecurrent disease in terms of relapsed oligometastatic phase; (3) oligoprogressive patients after cytoreductive treatment. The aim of the present review is to analyze available data concerning the efficacy/safety of SBRT for oligometastatic/oligoprogressive/oligorecurrent lung metastases...
April 1, 2018: Tumori
https://www.readbyqxmd.com/read/29707323/long-term-survival-without-surgery-in-nsclc-patients-with-synchronous-brain-oligometastasis-systemic-chemotherapy-revisited
#13
Jun Sato, Hidehito Horinouchi, Yasushi Goto, Shintaro Kanda, Yutaka Fujiwara, Hiroshi Nokihara, Noboru Yamamoto, Yuichiro Ohe
Background: Among patients with metastatic non-small-cell lung cancer (NSCLC), patients with TNM stage N0 to N1 and brain oligometastases (BOM) (less than 5 metastases) as the sole distant lesion (N0-1 BOM) who receive surgical treatments for the primary and metastatic sites reportedly have a better prognosis. Little data is available regarding the outcomes of patients treated with only systemic chemotherapy for the primary site and definitive treatment for synchronous BOM, compared with the outcomes of patients receiving surgical treatment for the primary site...
March 2018: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29706460/local-control-and-fracture-risk-following-stereotactic-body-radiation-therapy-for-non-spine-bone-metastases
#14
Darby Erler, Drew Brotherston, Arjun Sahgal, Patrick Cheung, Andrew Loblaw, William Chu, Hany Soliman, Hans Chung, Alex Kiss, Edward Chow, Ian Poon
AIMS: To report local control and toxicity rates for patients treated with stereotactic body radiotherapy (SBRT) for non-spine bone metastases. METHODS AND MATERIALS: Eighty-one patients with 106 non-spine bone metastases were treated between 2011 and 2014 and retrospectively reviewed. Indications included: oligometastases (63%), oligoprogression (17.3%), retreatment (2.4%) or other (17.3%). Cumulative incidence function was used to assess local recurrence and fracture probability...
April 26, 2018: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/29695273/stereotactic-body-radiotherapy-for-central-lung-tumors-yes-we-can
#15
Yasmin Korzets Ceder, Eyal Fenig, Aron Popvtzer, Nir Peled, Mordechai R Kramer, Milton Saute, Dima Bragilovsky, Tzippy Schochat, Aaron M Allen
BACKGROUND: SBRT is standard therapy for early stage lung cancer. Toxicity in central tumors has been a concern. RTOG 0813 showed that central SBRT is safe and effective. We report our experience with central SBRT. METHODS: We reviewed the records of patients treated with SBRT for central lung tumors (< 2 cm of the carina). Patients included primary lung cancer and recurrence following surgery and\ or conventional radiotherapy. All patients underwent 4DCT simulation and treatment planning was done with IMRT or VMAT techniques...
April 25, 2018: Radiation Oncology
https://www.readbyqxmd.com/read/29671075/stereotactic-body-radiotherapy-for-castration-sensitive-prostate-cancer-bone-oligometastases
#16
Giuseppe Fanetti, Giulia Marvaso, Delia Ciardo, Annaisabel Rese, Rosalinda Ricotti, Elena Rondi, Stefania Comi, Federica Cattani, Dario Zerini, Cristiana Fodor, Ottavio de Cobelli, Roberto Orecchia, Barbara A Jereczek-Fossa
To evaluate outcome in patients treated with stereotactic body radiotherapy (SBRT) on bone oligometastases from castration-sensitive prostate cancer after primary treatment. We retrospectively collected data of patients with less than five lesions at time of SBRT and hormone-naïve disease at the first extra-regional localization, treated between 03/2012 and 11/2016. Prostate-specific antigen (PSA) was measured every 3 months after SBRT. Imaging was performed in case of progression. Survival analysis was performed with Kaplan-Meier (log-rank test) approach...
April 18, 2018: Medical Oncology
https://www.readbyqxmd.com/read/29663172/individual-changes-in-neurocognitive-functioning-and-health-related-quality-of-life-in-patients-with-brain-oligometastases-treated-with-stereotactic-radiotherapy
#17
Pim B van der Meer, Esther J J Habets, Ruud G Wiggenraad, Antoinette Verbeek-de Kanter, Geert J Lycklama À Nijeholt, Hanneke Zwinkels, Martin Klein, Linda Dirven, Martin J B Taphoorn
BACKGROUND: Recently, it has been shown that at group level, patients with limited brain metastases treated with stereotactic radiotherapy (SRT) maintain their pre-treatment levels of neurocognitive functioning (NCF) and health-related quality of life (HRQoL). The aim of this study was to evaluate NCF and HRQoL changes over time at the individual patient level. METHODS: NCF (seven domains assessed with a standardized test battery) and HRQoL (eight predetermined scales assessed with the EORTC QLQ-C30 and BN20 questionnaires) were measured prior to SRT and at 3 and/or 6 months follow-up...
April 16, 2018: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/29651809/development-of-chemotherapy-and-significance-of-conversion-surgery-after-chemotherapy-in-unresectable-pancreatic-cancer
#18
REVIEW
Junji Furuse, Junji Shibahara, Masanori Sugiyama
While surgery currently remains the only potentially curative treatment available for pancreatic cancer, only 20% to 30% of patients have resectable disease at diagnosis. Recently, with the introduction of intensive chemotherapy regimens such as oxaliplatin, irinotecan, fluorouracil plus leucovorin (FOLFIRINOX) and gemcitabine plus nab-paclitaxel, for the treatment of unresectable pancreatic cancer, the antitumor activity and overall survival in patients with pancreatic cancer have dramatically improved. These advances in intensive chemotherapy have led to the possibility of conversion of unresectable disease to resectable disease, and it has been reported that more than 20% of pancreatic cancer patients with unresectable locally advanced disease at diagnosis undergo successful conversion surgery after FOLFIRINOX therapy...
May 2018: Journal of Hepato-biliary-pancreatic Sciences
https://www.readbyqxmd.com/read/29644155/stereotactic-body-radiation-therapy-for-pulmonary-oligometastases-arising-from-non-lung-primaries-in-patients-without-extrapulmonary-disease
#19
Michael J Dohopolski, Zachary Horne, David Clump, Steven A Burton, Dwight E Heron
Purpose Stereotactic body radiation therapy (SBRT) is increasingly used in the management of patients with oligometastatic cancers and is under prospective evaluation by the Radiation Therapy Oncology Group (RTOG). Here we report outcomes from a high-volume institution of patients treated with SBRT for pulmonary oligometastases. Materials and methods We conducted a retrospective review of 105 patients who had one to five pulmonary oligometastases (185 lesions) without extrapulmonary disease treated with SBRT from 2002-2014...
February 7, 2018: Curēus
https://www.readbyqxmd.com/read/29589221/long-term-survival-with-repeat-resection-for-lung-oligometastasis-from-pancreatic-ductal-adenocarcinoma-a-case-report
#20
Ryota Matsuki, Masanori Sugiyama, Hidefumi Takei, Haruhiko Kondo, Masachika Fujiwara, Junji Shibahara, Junji Furuse
BACKGROUND: Long-term survival after resection of metastases from pancreatic ductal adenocarcinoma is rare. CASE PRESENTATION: A 54-year-old man underwent pancreaticoduodenectomy (PD) for pancreatic ductal adenocarcinoma (PDAC) with UICC staging pT3N1M0 followed by adjuvant chemotherapy with gemcitabine (GEM). Three years after radical resection of the primary tumor, a tiny nodule was found in the lower lobe of the left lung. Despite treatment with GEM, it increased gradually, but no other metastases were found...
March 27, 2018: Surgical Case Reports
keyword
keyword
107559
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"